22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › BLUEPRINT MEDICINES CORP. › 2024-2025

BLUEPRINT MEDICINES CORP. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and BLUEPRINT MEDICINES CORP.’s Form 8-K, filed June 20, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 373Asset managers, any item
  • 2,534Fund votes
  • June 18, 2025Meeting date

Results at a glance

Meeting of June 18, 2025: 5 items on BLUEPRINT MEDICINES CORP.’s Form 8-K, filed June 20, 2025: 2 approved · 3 passed (calculated).

Dissent

Significant dissent: 3 directors (25.8%, 22.4%, 21.0% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025

Explore BLUEPRINT MEDICINES CORP. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by BLUEPRINT MEDICINES CORP.

These tallies are BLUEPRINT MEDICINES CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 20, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BLUEPRINT MEDICINES CORP. — official shareholder meeting results, meeting held June 18, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Jeffery W. Albers 44,683,223---- 15,507,4152,342,656 74%Passed (calculated)—
Elect Director: Mark Goldberg, M.D. 46,734,594---- 13,456,0442,342,656 78%Passed (calculated)—
Elect Director: John Tsai, M.D. 47,572,890---- 12,617,7482,342,656 79%Passed (calculated)—
2. Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. 57,714,0692,450,82525,744 --2,342,656 96%Approved—
3. Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting for the fiscal year ending December 31, 2025. 62,209,853288,58034,861 ---- 99.5%Approved—

Source: BLUEPRINT MEDICINES CORP., Form 8-K, filed with the SEC on June 20, 2025 — read the filing on EDGAR.

How asset managers voted at the BLUEPRINT MEDICINES CORP. 2024-2025 meeting

373 asset managers disclosed a vote on at least one BLUEPRINT MEDICINES CORP. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Jeffery W. Albers

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD
FOR: 44,683,223WITHHELD: 15,507,415
Details: description as filed, official tally, votes by 102 asset managers

Description as filed by funds: Election of class I directors each to serve for a three-year term, or until their successor has been duly elected and qualified: Jeffrey Albers

BLUEPRINT MEDICINES CORP.’s own tally for this item (“Elect Director: Jeffery W. Albers”): 44,683,223 for, 15,507,415 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 102 asset managers below reported 28,128,126 for, 5,085,675 withheld, 519,354 abstained.

FORWITHHOLD
FOR: 28,128,126ABSTAIN: 519,354WITHHOLD: 5,085,675
Largest asset managers voting on “Election of class I directors each to serve for a three-year term, or until their successor has been duly elec” at BLUEPRINT MEDICINES CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,346,0690 02,400For
T. Rowe Price5,315,4750 021,550For
BlackRock2,524,6310 00For
Fidelity2,339,7240 0200For
JPMorgan2,017,4980 00For
State Street3,3390 01,158,395Withhold
Delaware/Macquarie00 0955,278Withhold
MUTUAL FUND SERIES TRUST859,4620 00For
Invesco621,8990 00For
Charles Schwab604,9930 00For
TIAA543,5800 00For
Manager Directed Portfolios519,0740 00For
Jackson National381,6830 112,7840Mixed
ACAP Strategic Fund00 0444,988Withhold
AllianceBernstein382,5170 00For
Capital Group367,1240 00For
Legg Mason342,3000 03,400For
American Century00 0342,227Withhold
Columbia Threadneedle336,0590 00For
Goldman Sachs291,7340 020,507Mixed
WILLIAM BLAIR FUNDS00 0298,044Withhold
Equitable271,2020 00For
MFS00 0260,458Withhold
Principal77,6550 0148,280Mixed
AB DISCOVERY GROWTH FUND, INC.207,7030 00For

Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).

Elect Director: John Tsai, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD
FOR: 47,572,890WITHHELD: 12,617,748
Details: description as filed, official tally, votes by 102 asset managers

Description as filed by funds: Election of class I directors each to serve for a three-year term, or until their successor has been duly elected and qualified: John Tsai, M.D.

BLUEPRINT MEDICINES CORP.’s own tally for this item (“Elect Director: John Tsai, M.D.”): 47,572,890 for, 12,617,748 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 102 asset managers below reported 29,526,743 for, 3,707,678 withheld, 498,734 abstained.

FOR
FOR: 29,526,743ABSTAIN: 498,734WITHHOLD: 3,707,678
Largest asset managers voting on “Election of class I directors each to serve for a three-year term, or until their successor has been duly elec” at BLUEPRINT MEDICINES CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,346,0690 02,400For
T. Rowe Price5,315,4750 021,550For
BlackRock2,524,6310 00For
Fidelity2,339,7240 0200For
JPMorgan2,017,4980 00For
State Street1,160,2530 01,481For
Delaware/Macquarie00 0955,278Withhold
MUTUAL FUND SERIES TRUST859,4620 00For
Invesco621,8990 00For
Charles Schwab604,9930 00For
TIAA543,5800 00For
Manager Directed Portfolios519,0740 00For
Jackson National381,6830 112,7840Mixed
ACAP Strategic Fund00 0444,988Withhold
AllianceBernstein382,5170 00For
Capital Group367,1240 00For
Legg Mason342,3000 03,400For
American Century00 0342,227Withhold
Columbia Threadneedle336,0590 00For
Goldman Sachs291,7340 020,507Mixed
WILLIAM BLAIR FUNDS00 0298,044Withhold
Equitable271,2020 00For
MFS00 0260,458Withhold
Principal77,6550 0148,280Mixed
AB DISCOVERY GROWTH FUND, INC.207,7030 00For

Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).

Elect Director: Mark Goldberg, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD
FOR: 46,734,594WITHHELD: 13,456,044
Details: description as filed, official tally, votes by 102 asset managers

Description as filed by funds: Election of class I directors each to serve for a three-year term, or until their successor has been duly elected and qualified: Mark Goldberg, M.D.

BLUEPRINT MEDICINES CORP.’s own tally for this item (“Elect Director: Mark Goldberg, M.D.”): 46,734,594 for, 13,456,044 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 102 asset managers below reported 29,487,026 for, 3,726,775 withheld, 519,354 abstained.

FOR
FOR: 29,487,026ABSTAIN: 519,354WITHHOLD: 3,726,775
Largest asset managers voting on “Election of class I directors each to serve for a three-year term, or until their successor has been duly elec” at BLUEPRINT MEDICINES CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,346,0690 02,400For
T. Rowe Price5,315,4750 021,550For
BlackRock2,524,6310 00For
Fidelity2,339,7240 0200For
JPMorgan2,017,4980 00For
State Street1,160,2530 01,481For
Delaware/Macquarie00 0955,278Withhold
MUTUAL FUND SERIES TRUST859,4620 00For
Invesco621,8990 00For
Charles Schwab604,9930 00For
TIAA543,5800 00For
Manager Directed Portfolios519,0740 00For
Jackson National381,6830 112,7840Mixed
ACAP Strategic Fund00 0444,988Withhold
AllianceBernstein382,5170 00For
Capital Group367,1240 00For
Legg Mason342,3000 03,400For
American Century00 0342,227Withhold
Columbia Threadneedle336,0590 00For
Goldman Sachs291,7340 020,507Mixed
WILLIAM BLAIR FUNDS00 0298,044Withhold
Equitable271,2020 00For
MFS00 0260,458Withhold
Principal77,6550 0148,280Mixed
AB DISCOVERY GROWTH FUND, INC.207,7030 00For

Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).

2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 10 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 57,714,069AGAINST: 2,450,825

Prior year: 97.7% for (June 12, 2024 meeting) ▼ 1.8 pts

Details: description as filed, official tally, votes by 371 asset managers

Description as filed by funds: APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

BLUEPRINT MEDICINES CORP.’s own tally for this item (“2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”): 57,714,069 for, 2,450,825 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 102 asset managers voting on “APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at BLUEPRINT MEDICINES CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,348,4663 00For
T. Rowe Price5,337,0250 00For
BlackRock2,524,6310 00For
Fidelity2,339,9240 00For
JPMorgan2,017,4980 00For
State Street1,160,2411,493 00For
Delaware/Macquarie955,2780 00For
MUTUAL FUND SERIES TRUST859,4620 00For
Invesco0621,899 00Against
Charles Schwab604,9930 00For
TIAA543,5800 00For
Manager Directed Portfolios519,0740 00For
Jackson National370,266124,201 00Mixed
ACAP Strategic Fund444,9880 00For
AllianceBernstein382,5170 00For
Capital Group367,1240 00For
Legg Mason345,7000 00For
American Century0342,227 00Against
Columbia Threadneedle336,0590 00For
Goldman Sachs312,2410 00For
WILLIAM BLAIR FUNDS298,0440 00For
Equitable271,2020 00For
MFS260,4580 00For
Principal225,9350 00For
AB DISCOVERY GROWTH FUND, INC.207,7030 00For

Fund voting reports, all 102 managers: 32,444,098 for, 1,244,963 against, 19,018 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 296 asset managers voting on “APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at BLUEPRINT MEDICINES CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price7,650,8060 00For
Avoro Capital Advisors LLC3,863,0220 00For
JPMorgan2,968,8830 00For
Wellington2,595,8110 00For
State Street2,402,6192,420 00For
BlackRock2,318,1590 00For
GEODE CAPITAL MANAGEMENT, LLC1,532,4670 00For
Fidelity1,255,5650 00For
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC1,228,2200 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST1,167,2370 00For
AllianceBernstein1,094,8410 00For
Hood River Capital Management LLC889,5700 00For
Rock Springs Capital Management LP865,2560 00For
PICTET ASSET MANAGEMENT SA772,9600 00For
Invesco0740,036 00Against
Clearbridge Investments, LLC673,9150 00For
American Century0628,907 00Against
Siren, L.L.C.623,8700 00For
Charles Schwab617,4030 00For
Nuveen590,2040 00For
Northern Trust497,3300 00For
BROWN ADVISORY INC488,3640 00For
BRAIDWELL LP445,7360 00For
Woodline Partners LP418,8730 00For
Capital Research Global Investors367,1240 00For

Institutional-manager reports, all 296 managers: 43,292,631 for, 1,841,469 against, 25,100 withheld, 1,490 abstained, 1,659 not voted. Showing the 25 largest; every one is in the interactive database (link above).

3. The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.5% Approved · of votes cast

FOR 99.5%
FOR: 62,209,853AGAINST: 288,580
Details: description as filed, official tally, votes by 104 asset managers

Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

BLUEPRINT MEDICINES CORP.’s own tally for this item (“3. The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting for the fiscal year ending December 31, 2025.”): 62,209,853 for, 288,580 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting for the fiscal year ending December 31, 2025.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 104 asset managers below reported 33,702,990 for, 12,323 against, 19,018 abstained.

FOR
FOR: 33,702,990AGAINST: 12,323ABSTAIN: 19,018
Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for ” at BLUEPRINT MEDICINES CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,348,4690 00For
T. Rowe Price5,337,0250 00For
BlackRock2,524,6310 00For
Fidelity2,339,9240 00For
JPMorgan2,017,4980 00For
State Street1,161,66668 00For
Delaware/Macquarie955,2780 00For
MUTUAL FUND SERIES TRUST859,4620 00For
Invesco621,8990 00For
Charles Schwab604,9930 00For
TIAA543,5800 00For
Manager Directed Portfolios519,0740 00For
Jackson National494,4670 00For
ACAP Strategic Fund444,9880 00For
AllianceBernstein382,5170 00For
Capital Group367,1240 00For
Legg Mason345,7000 00For
American Century342,2270 00For
Columbia Threadneedle336,0590 00For
Goldman Sachs312,2410 00For
WILLIAM BLAIR FUNDS298,0440 00For
Equitable271,2020 00For
MFS260,4580 00For
Principal225,9350 00For
AB DISCOVERY GROWTH FUND, INC.207,7030 00For

Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).

Largest BLUEPRINT MEDICINES CORP. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 64,582,163 shares outstanding at the time of that meeting.

Fund voting reports: top BLUEPRINT MEDICINES CORP. shareholders by shares voted on “APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 12.93%
2T. Rowe Price 8.26%
3BlackRock 3.91%
4Fidelity 3.62%
5JPMorgan 3.12%
6State Street 1.80%
7Delaware/Macquarie 1.48%
8MUTUAL FUND SERIES TRUST 1.33%
9Invesco 0.96%
10Charles Schwab 0.94%
Institutional-manager reports: top BLUEPRINT MEDICINES CORP. shareholders by shares voted on “APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE…”, 2024-2025
#Asset manager % of shares outstanding
1T. Rowe Price 11.85%
2Avoro Capital Advisors LLC 5.98%
3JPMorgan 4.60%
4Wellington 4.02%
5State Street 3.72%
6BlackRock 3.59%
7GEODE CAPITAL MANAGEMENT, LLC 2.37%
8Fidelity 1.94%
9WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 1.90%
10MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST 1.81%

Reported BLUEPRINT MEDICINES CORP. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

BLUEPRINT MEDICINES CORP. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock6,710,708 10.39%Form 13F, quarter ended March 31, 2025
Vanguard Group6,640,523 10.28%Form 13F, quarter ended March 31, 2025
T. Rowe Price5,415,837 8.39%Form 13F, quarter ended March 31, 2025
Pentwater Capital Management LP3,900,000 6.04%Schedule 13G, filed August 14, 2025
Wellington Management3,073,306 4.76%Form 13F, quarter ended March 31, 2025
State Street2,684,117 4.16%Form 13F, quarter ended March 31, 2025
JPMorgan Chase2,506,514 3.88%Form 13F, quarter ended March 31, 2025
Geode Capital1,522,647 2.36%Form 13F, quarter ended March 31, 2025
FMR (Fidelity)1,433,169 2.22%Form 13F, quarter ended March 31, 2025
Invesco984,674 1.52%Form 13F, quarter ended March 31, 2025

Percentages above are of 64,582,163 shares outstanding, as reported by BLUEPRINT MEDICINES CORP. on its Form 10-Q dated April 29, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At BLUEPRINT MEDICINES CORP.'s shareholder meeting held June 18, 2025, in the 2024-2025 proxy season, 373 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 2,534 separate fund positions. On the most widely held item on that ballot — APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE… — BLUEPRINT MEDICINES CORP.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BLUEPRINT MEDICINES CORP.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 20, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BLUEPRINT MEDICINES CORP.’s 10-Q dated April 29, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

BLUEPRINT MEDICINES CORP. proxy season coverage: 2023-2024 · 2024-2025 (this page).

Cite this page

Proxy Votes Now, “BLUEPRINT MEDICINES CORP. 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/blueprint-medicines-corp/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.